ArticlebioRxiv : the preprint server for biology2025

Silmitasertib, an FDA-designated orphan CK2 Inhibitor, ameliorates neuropathology and motor dysfunction in a Huntington's disease mouse model.

Ross J Pelzel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.